Navigation Links
Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
Date:1/20/2009

MOUNTAIN VIEW, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiated a Phase 2b clinical trial with AZ-104 (Staccato loxapine) in patients with migraine headaches. AZ-104 is a lower-dose version of AZ-004 (Staccato loxapine), Alexza's lead product candidate that is in late Phase 3 clinical development for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. The Company has previously announced positive results in two Phase 3 trials of AZ-004 and expects to submit a New Drug Application for AZ-004 in early 2010. AZ-104 and AZ-004 are being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC.

The AZ-104 Phase 2b clinical trial is an outpatient, multi-center, randomized, double-blind, single-dose, placebo-controlled study in approximately 360 patients who have migraines, with or without aura. Three doses will be evaluated in the clinical trial, placebo and two doses of AZ-104 (1.25 and 2.5 mg). The primary efficacy endpoint for the trial is headache pain relief at 2 hours post-dose, using the standard 4-point rating scale (International Headache Society). Secondary efficacy endpoints for the trial include pain relief and other symptom assessments at various time points. Safety evaluations will also be made throughout the clinical trial period.

"We previously announced initial results with AZ-104 in an in-clinic setting, showing its positive effect treating pain and other key symptoms of migraine headache," said Thomas B. King, Alexza President and CEO. "We believe the potential value of the non-invasive nature and rapid onset of pharmacological action provided by our Staccato system is well-suited for migraine pain relief in the outpatient set
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)... 27, 2015 ieCrowd™ today announced the ... development of the company,s supplemental oxygen delivery device, ... being developed by ieCrowd,s subsidiary Smart Oxygen Solutions ... demand for oxygen based on level of activity.  ... for the Smart Oxygen device would require a ...
(Date:8/27/2015)... , Aug. 27, 2015  Now that Intuitive ... Da Vinci S™ surgical robot, hospitals with robotic surgery ... They also need to see where they stand with ... the right patients? Have they adopted best practices for ... program in the future? ECRI Institute, which ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3
... Texas, April 8, 2011 Novation, the leading health ... St. Jude Medical (St. Paul, MN) to its portfolio ... St. Jude Medical is a leading provider of ... patients. The company provides a full portfolio of arrhythmia ...
... April 8, 2011 Pacira Pharmaceuticals, Inc. (NASDAQ: ... Scibetta, chief financial officer, is scheduled to present at the ... April 15, 2011, at 11:30 a.m. EDT being held at ... City. Mr. Scibetta is expected to present an overview of ...
Cached Medicine Technology:Novation Announces the Addition of St. Jude Medical to the Cardiac Rhythm Management Products Portfolio 2Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference 2
(Date:8/30/2015)... ... August 31, 2015 , ... This month, top rated New ... assisted living facilities and nursing homes protect their residents from neglect and improper ... experts at the company, security systems don’t just protect; they also help monitor ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... that Brian Spector has joined the company as the new Global Communications Director ... broadcasting and public relations experience having spent the last 16 years doing on-air ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... devices for the treatment of prostate cancer, has announced the roll-out of its ... the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in ...
(Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor Day weekend, the last ... on September 22nd this year). For IT security personnel, it should also mark the ... prove far more costly than a simple headache. , Joe Caruso, founder and CEO-CTO ...
Breaking Medicine News(10 mins):Health News:Total Security Announces Security Systems Tips for New York Assisted Living Facilities and Nursing Homes 2Health News:Total Security Announces Security Systems Tips for New York Assisted Living Facilities and Nursing Homes 3Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... thrombosis linked to deep vein thrombosis, study says , ... condition -- superficial vein thrombosis, or varicose veins that ... presence of a more dangerous problem. , One-quarter of ... study actually had deep vein thrombosis (DVT), a potentially ...
... metastasis, researchers say , MONDAY, July 20 (HealthDay News) ... contribute to aggressive breast cancer, new research shows. , ... of breast cancer tumors, researchers from the Genome Institute ... implicated in the development of breast cancer. , They ...
... , , , ... the "Door to Door" program for patients with multiple myeloma. Cancer Care ,s ... patients for covering transportation costs such as gasoline and taxi, bus or train ... The program is funded in part by a generous grant from ...
... , CBO Announcement Says Current Legislation Does Not ... , WASHINGTON, July 20 In response to a recent ... the Senate and House, the PFCD urges Congress to address the number-one ... , "The Senate HELP and House Ways ...
... School and Amtek, Hanover, NH may treat tumors that do ... on May 29th in the open access, peer reviewed journal ... to selectively kill tumors while protecting healthy cells. In ... as methylthioadenosine phosphorylase (MTAP) is missing in 35 to ...
... one of only four sites across the country to participate ... study will investigate the effectiveness of a chemotherapeutic agent, ThermoDox, ... therapy) for treating recurrent chest wall breast cancer. ... breast cancer on the chest wall, most commonly presenting in ...
Cached Medicine News:Health News:Vein Condition May Mask Serious Clot Disorder 2Health News:New Gene May Signal Aggressive Breast Cancer 2Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 2Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 3Health News:PFCD Urges Congress to Address Real Cost-Driver in Health Reform in Light of New CBO Statement 2Health News:New strategy in tumor treatment 2Health News:RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer 2
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for thecontrol of percision for up to 10 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: